Stay updated on Pembrolizumab and Chemoradiation in Head and Neck Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Chemoradiation in Head and Neck Clinical Trial page.

Latest updates to the Pembrolizumab and Chemoradiation in Head and Neck Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe record presents details of the completed Phase 3 KEYNOTE-412 study comparing pembrolizumab plus chemoradiation with placebo plus chemoradiation for locally advanced head and neck squamous cell carcinoma. It also provides trial results, eligibility requirements, participating locations, publications, and study documents.SummaryDifference100%

- Check16 days agoChange DetectedThe footer now identifies site revision v3.8.0 instead of v3.7.2; the study record remains unavailable behind a 403 Forbidden response.SummaryDifference0.2%

- Check23 days agoChange DetectedA site-wide notice announces NIH updates and says that “Super Intelligence” will be used in place of “Artificial Intelligence” during a transition.SummaryDifference1%

- Check30 days agoChange DetectedThe footer revision label changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check37 days agoChange DetectedThe ClinicalTrials.gov footer revision changed from v3.7.0 to v3.7.1. The page still displays a 403 Forbidden error rather than the study record.SummaryDifference0.2%

- Check51 days agoChange DetectedThe page now shows a 403 Forbidden error with the standard site chrome; access to the study record is blocked rather than updated content, reflecting an access restriction rather than a page change.SummaryDifference0.5%

Stay in the know with updates to Pembrolizumab and Chemoradiation in Head and Neck Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Chemoradiation in Head and Neck Clinical Trial page.